55 reports of this reaction
3.2% of all NAFCILLIN SODIUM reports
#3 most reported adverse reaction
DRUG INEFFECTIVE is the #3 most commonly reported adverse reaction for NAFCILLIN SODIUM, manufactured by Athenex Pharmaceutical Division, LLC.. There are 55 FDA adverse event reports linking NAFCILLIN SODIUM to DRUG INEFFECTIVE. This represents approximately 3.2% of all 1,697 adverse event reports for this drug.
Patients taking NAFCILLIN SODIUM who experience drug ineffective should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG INEFFECTIVE is moderately reported among NAFCILLIN SODIUM users, representing a notable but not dominant share of adverse events.
In addition to drug ineffective, the following adverse reactions have been reported for NAFCILLIN SODIUM:
The following drugs have also been linked to drug ineffective in FDA adverse event reports:
DRUG INEFFECTIVE has been reported as an adverse event in 55 FDA reports for NAFCILLIN SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG INEFFECTIVE accounts for approximately 3.2% of all adverse event reports for NAFCILLIN SODIUM, making it one of the most commonly reported side effect.
If you experience drug ineffective while taking NAFCILLIN SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.